StreetAlpha
13F holdings · Q3 2026

Catalio Capital Management

New York, NY · files as Catalio Capital Management, LP
Know the moment Catalio Capital Management filesYou follow Catalio Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1958125

Catalio Capital Management reported 47 stocks worth $538M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVLN (9.0%), BMY (5.8%) and BBIO (5.2%). Compared with Q2 2026, the fund opened new positions in ARWR, CELC and GH, added to AVLN, BMY and ASND, trimmed BBIO, JNJ and SNDX and sold out of GILD, INCY and AXSM.

Latest filing: what Catalio Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
14 new13 added14 trimmed6 sold outBought about $185M · sold about $155M
New 14
See all 14 →
Added 13
See all 13 →
Trimmed 14
See all 14 →
Sold out 6
See all 6 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$538M+1.2% vs last quarter
Stocks held4714 new · 6 sold out
Top 5 weight29.8%spread out
Turnover63%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
AVLN
Avalyn Pharma Inc
$48.4M9.0%1.7M+23K (+1%)2 of 8
2
BMY
Bristol Myers Squibb Co
$31.2M5.8%500K+87K (+21%)5 of 8
3
BBIO
Bridgebio Pharma Inc
$28M5.2%425K−30K (−7%)7 of 8
4
PBLS
Parabilis Medicines Inc Com
$26.6M4.9%824KNo change2 of 8
5
JNJ
Johnson & Johnson
$26.3M4.9%99K−39K (−28%)3 of 8
6
ASND
Ascendis Pharma A/s
$23.1M4.3%101K+70K (+219%)2 of 8
7
ARWR
Arrowhead Pharmaceuticals in
$20.6M3.8%315KNew position1 of 8
8
SNDX
Syndax Pharmaceuticals Inc
$19.2M3.6%1M−192K (−16%)7 of 8
9
DFTX
Definium Therapeutics Inc
$19M3.5%498K−65K (−12%)3 of 8
10
CELC
Celcuity Inc
$18.3M3.4%231KNew position1 of 8
🔒 37 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
GILD
Gilead Sciences Inc
$34M269K
INCY
Incyte Corp
$21.7M192K
AXSM
Axsome Therapeutics Inc
$10.6M43K
DYN
Dyne Therapeutics Inc
$5.4M245K
DNTH
Dianthus Therapeutics Inc
$3.2M33K

🔒 Free account: see all 6.

Reported value

last 8 quarters
$457MQ4 '24
$403MQ1 '25
$477MQ2 '25
$541MQ3 '25
$566MQ4 '25
$479MQ1 '26
$532MQ2 '26
$538MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Catalio Capital Management 13F FAQ

What does Catalio Capital Management own?

Catalio Capital Management reported 47 stocks worth $538M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVLN (9.0%), BMY (5.8%) and BBIO (5.2%). The table above lists every position in the filing (the top 10 without an account).

What did Catalio Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 14 new positions, 13 added to, 14 trimmed and 6 sold out. New positions include ARWR, CELC and GH. It sold all of GILD, INCY and AXSM.

When will Catalio Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Catalio Capital Management's portfolio worth?

The Q3 2026 filing reports $538M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.